ClinicalTrials.gg
Active, not recruitingNCT04304040Updated Feb 7, 2024

A Study of MIL62 Combined With Orelabrutinib for the Treatment of R/R CD20+B Cell Lymphoma

A Phase 1/2 interventional study of Orelabrutinib and Recombinant humanized monoclonal antibody MIL62 injection in B-cell Lymphoma Recurrent and B-cell Lymphoma Refractory, sponsored by Beijing InnoCare Pharma Tech Co., Ltd.. Active, not recruiting at 10 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Beijing InnoCare Pharma Tech Co., Ltd. (part of InnoCare Pharma Limited) · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 283 studies in Lymphoma, B-Cell with a site in China — 125 open to participants now, 146 under way, 9 of them phase 3. Lymphoma, B-Cell · China.

Enrollment
104th of 273
43 · median 30
Started
2020
with 21 others
Phase 1/2
58 of 283
24 open now
Primary completion
2025-12
later than 30 of 145 live
Registered
86th of 283
by date

Among the 283 studies in Lymphoma, B-Cell with a site in China, this one is the 104th largest by enrollment of the 273 interventional ones that give a count, is one of 22 that started in 2020, is one of 58 in phase 1/2, reaches primary completion later than 30 of the 145 other live ones, and was the 86th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

125 of the 283 studies in Lymphoma, B-Cell with a site in China are open now. Recruiting first, the newest first:

120 more — sign in →

All 125 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 283 studies in Lymphoma, B-Cell with a site in China, or all of them as a file.
02

Study summary

Dose escalation and expansion phase I/IIa clinical study of recombinant humanized type II CD20 monoclonal antibody MIL62 injection combined with a novel selective Bruton Tyrosine Kinase(BTK) inhibitor Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma

03

Conditions studied

  • B-cell Lymphoma Recurrent
  • B-cell Lymphoma Refractory

Browse trials for

Keywords

  • CD20+
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years, gender not limited
  2. Dose escalation phase: confirmed CD20 positive B-cell non-Hodgkin's lymphoma; Expansion stage: R/R NHL Or histologically diagnosed CD20 positive chronic lymphocytic leukemia/small lymphocytic lymphoma;
  3. Dose escalation phase :Patients who have received at least one treatment regimen Expansion stage:Patients who have received at least one to four treatment regimens with at least one regimen containing rituximab;
  4. Eastern cancer collaboration group() physical status score: 0-2
  5. Laboratory tests performed within 7 days prior to the first acceptance of the study drug met the protocol criteria.
  6. Expected survival ≥6 months
  7. Sign a written .

Exclusion criteria

Exclusion Criteria:

  1. Expansion stage: DLBCL transformed from follicular lymphoma, DLBCL with follicular lymphoma, and lymphomas with primary or central nervous system involvement.
  2. Received any of the anti-tumor treatments(note in the protocol) before the first study drug.
  3. Previous use of any anticancer vaccine.
  4. Patients who had received hematopoietic stem cell transplantation within 3 months before the first administration
  5. Patients scheduled for major surgery within 28 days prior to initial administration or during the expected study period.
  6. Patients who Is participating in other clinical trials or first administration less than 28 days after the end of the previous clinical trial.
  7. Receiving prednisone treatment or other treatment with the same dose as prednisone ;Patients who require warfarin or an equivalent vitamin K antagonist;
  8. During the study period, drugs with moderate or severe inhibition or strong induction of cytochrome were taken together;
  9. Subject has a history of any of the diseases note in the protocol;
  10. Patients with infections;
  11. Impact testing scheme compliance or other serious results explain the poor control of the merger of the disease(note in the protocol);
  12. Toxicity of any previous anticancer treatment has not recovered to ≤1, except for hair loss;
  13. A history of severe allergic reactions to humanized monoclonal antibodies or known allergies to any component of Orelabrutinib or MIL62;
  14. Inability to swallow research drugs, or the presence of conditions that significantly affect gastrointestinal function;
  15. surface antigen (HBsAg) and/or hepatitis b core antibody (HBcAb) are positive ; virus (HCV) antibody positive and HCV RNA positive patients; (HIV) serum response was positive;
  16. Pregnant and lactating women; For women of childbearing age who have not undergone sterilization surgery: do not agree to use appropriate methods of ;
  17. For men not undergoing sterilization: do not agree to use the barrier method of contraception;
  18. Other circumstances considered inappropriate for the study by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Single Arm

    Drug: Orelabrutinib · Drug: Recombinant humanized monoclonal antibody MIL62 injection

Interventions

  • BTK inhibitor Orelabrutinib low dose or high dose; Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.

  • Recombinant humanized monoclonal antibody MIL62 injection, 800mg or1000mg each time, Part A:28days/cycle, Cycle1:35days; Part B:21 days/cycle, Cycle1:28days.

06

What researchers measure

Primary outcomes

  1. Dose limiting toxicity (DLT)(Dose escalation phase)

    Safety observation indicator

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  2. Maximum tolerated dose (MTD) (Dose escalation phase)

    Safety observation indicator

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  3. Recommended dose for phase 2 trials of two-drug combinations (RP2D) (Dose escalation phase)

    Safety observation indicator

    Time frame: At the end of Cycle 1 (each cycle is 28 days)

  4. objective remission rate(ORR) (Dose expansion phase)

    Efficacy observation indicator

    Time frame: At the end of Cycle 30 (each cycle is 28 days)

Secondary outcomes

  1. objective remission rate(ORR)

    Efficacy observation indicator

    Time frame: At the end of Cycle 30 (each cycle is 28 days)

  2. Area under the plasma concentration vs time curve(AUC)

    pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment

    Time frame: At the end of Cycle 6 (each cycle is 28 days)

  3. Apparent half-life for designated elimination phases (t½)

    pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment

    Time frame: At the end of Cycle 6 (each cycle is 28 days)

  4. The peak plasma concentration (Cmax)

    pharmacokinetic parameter of MIL62 combined with Orelabrutinib in the treatment

    Time frame: At the end of Cycle 6 (each cycle is 28 days)

  5. Duration of remission(DOR)

    Efficacy observation indicator

    Time frame: 3 years after first treatment

  6. Progression-free survival(PFS) in the treatment of R/R CD20+B cell lymphoma

    Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of relapsed/refractory CD20+B cell lymphoma with 3-year progression-free survival

    Time frame: 3 years after first treatment

  7. overall survival(OS) in the treatment of R/R CD20+B cell lymphoma

    Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of recurrent/refractory CD20+B cell lymphoma with 3-year overall survival

    Time frame: 3 years after first treatment

  8. Duration of remission(DOR) in the treatment of R/R NHL

    Preliminary evaluation of remission duration of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma

    Time frame: 3 years after first treatment

  9. Progression-free survival(PFS) in the treatment of R/R NHL

    Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma with 3-year progression-free survival

    Time frame: 3 years after first treatment

  10. overall survival(OS) in the treatment of R/R NHL

    Preliminary evaluation of MIL62 combined with Orelabrutinib in the treatment of Recurrent/refractory Non Hodgkin Lymphoma with 3-year overall survival

    Time frame: 3 years after first treatment

07

Study locations

10 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2020 (actual). Primary completion is estimated for Dec 2025, 65 months after the start.

Of 94 phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 96. This study's planned 65 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2020
First posted
Mar 11, 2020
StartActual
Jul 28, 2020
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04304040
Responsible party
Sponsor
First posted
Mar 11, 2020
Start date
Jul 28, 2020
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Feb 7, 2024

Study contacts

Yuankai Shi, PhD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Orelabrutinib · Anti-CD20 Monoclonal Antibody MIL62

Start the discussion